The 2010 Investment U Conference is underway! And even if you couldn't make it, now you can "bring home" more than 30 breakthrough presentations from the conference... Order the Deluxe MP3/Video Library for $99 to listen and view on your computer, or the Premier CD plus MP3/Video Library for $149 to listen to and view anywhere.
by The Investment U Research Team
It was rumored that market recovery wouldn’t occur until the housing market turned itself around. For months it seemed a popular thing to say.
And why not? It makes sense that in order for millions of Americans to move forward, we needed to have a strong foundation first. Homes are the largest investment most people will make. An unstable housing market spells trouble for our fiscal stability.
There are some signs of life in the housing sector already, but the question remains whether vulture investors will be able to “lift the bottom” into a sustained real estate recovery.
Regardless, this is good news for homebuilders. As this excess inventory is pulled off the market, their prospects should increase. One of the most punished sectors, homebuilders have taken it one the chin, and their performance has mirrored the major indexes this year.
And even though the SPDR S&P Homebuilder Index ETF (NYSE: XHB) is still down roughly 8% for the year, it’s jumped over 30% since last month.
But there have been standouts. D.R. Horton (NYSE: DHI) and Pulte Homes (NYSE: PHM) have both outperformed their index and peers like Toll Brothers (NYSE: TOL).
In fact Moody’s just downgraded TOL.
Now if residential property is starting to move, what about commercial?
Unfortunately, things may not be looking as good. Standard & Poor just completed a study that indicates commercial real estate default rates should continue to rise. Specifically, they believe credit originated in 2005 to 2007 should do the worst.
Companies mentioned in this article: XHB, DHI, PHM and TOL.
- Mergers Heat Up Between Haves, Have-Nots
- Housing Numbers: The Truth Behind It All
- Bernanke’s No Help for FHA
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
Investment U RSS Feed